Acutaas Chemicals Ltd Q1 FY2025 Concall Summary

Key Takeaways

• 15% revenue growth, margin recovery underway: Revenue grew 15% YoY driven by Advanced Pharma, while gross margin improved 210 bps sequentially as pricing stabilized, though EBITDA margin remains well below last year's level.
• Baba Fine Chemicals is the drag: The semiconductor-grade specialty business is stuck at ~₹5 crores per quarter due to integration delays and end-customer headwinds, with recovery not expected until H2.
• Ankleshwar ramp-up is the swing factor: Blocks 2 and 3 are commissioning in Q2, with a European CDMO contract near signing; validation batches start next quarter, making this the primary margin and growth catalyst.
• Electrolyte business is still pre-revenue: The Enchem JV timeline is undefined, and electrolyte additives revenue won't begin until H2 FY25; the battery chemicals story remains a promise, not a contributor.
• What to watch next quarter: Whether the European CDMO contract is signed, whether Baba Fine Chemicals shows any sequential improvement, and whether gross margin expansion continues toward the 23% EBITDA target.

Revenue Drivers & Segment Performance

• Advanced Pharma leads: 16.6% YoY growth came from both CDMO and core product business, with the PMDA inspection success strengthening the value-chain position for Japanese customers.
• Specialty Chemicals mixed: 10% growth was driven by commodity chemicals; Baba Fine Chemicals remained subdued at ~₹5 crores per quarter, offsetting gains elsewhere.
• Volume over price: 18% volume growth was partially offset by ~3% pricing degrowth, reflecting the deliberate strategy to protect volumes with spot pricing to long-term customers that began in Q2 FY24.
• Q1 seasonality is structural: Q1 has always been the lowest revenue quarter since inception; the sequential degrowth was planned and visibility from customers supports the full-year 25% growth commitment.
• Apixaban ramp-up: Gradual shipments have started; the pickup accelerates in Q4 FY25, with FY26 as the peak sales year as exclusivity expires. Rivaroxaban peak sales also expected in FY26.

Naresh Patel: "Looking at our current order book, I am confident that we will comfortably meet our 25% growth guidance for the year."

Margin Trajectory & Profitability

• Sequential improvement is the story: Gross margin expanded 210 bps QoQ to 42.1% as RM prices stabilized and the company is moving back to old pricing formulas with most long-term customers.
• Path back to 20%+ EBITDA: Q4 FY24 demonstrated 19% EBITDA on ₹225 crores revenue at 40% gross margin; with 42% gross margin now and operational leverage on higher revenue, management sees more than 20% achievable in FY25, with 25%+ doable in Q3 and Q4.
• Depreciation and finance costs: Higher depreciation from Ankleshwar Block 1 capitalization will persist as remaining blocks come online; finance costs are expected to decline sharply with debt repayment.
• Solar savings unquantified: The 16 MW captive solar plant completes by end of Q2 FY25, with energy savings contributing to EBITDA from Q3, but management declined to quantify the impact.

Abhishek Patel: "Today, we are at a gross margin of 42% with operational efficiency and the large quantity of CDMO business, so more than 25% EBITDA level is definitely doable in this financial year also, hopefully in Q3 and Q4."

Baba Fine Chemicals: The Problem Child

• Integration bottleneck: Ownership transfer from Baba Fine Chem Partners to AMI required compliance work for end-customer Heraeus, consuming the past year. Heraeus is now facing headwinds in their final product, causing sluggishness over the last two quarters.
• New customer diversification underway: AMI is promoting other molecules to Korean and Japanese customers, already supplying at 1 kg to 10 kg levels. These new molecules carry 40–50% margins, below the 65% from Heraeus but far above current depressed levels.
• Approval timelines are long: Customer qualification can take 1–2 years depending on final product application, so the new customer pipeline is a medium-term story, not a quick fix.
• Recovery timeline: Management expects improvement to begin in H2 FY25, with the next 1–1.5 years seeing gains from both a Heraeus recovery and new customer ramp-up.

Naresh Patel: "This is a very highly entry barrier business, semiconductor and it's very difficult to enter in that system when you are doing with chemicals, which is high pure chemical."

Ankleshwar: The Growth Catalyst

• Block 1 capitalized, now operational: Full quarter depreciation impact hit Q1; the block is contributing to the CDMO and core product pipeline.
• Blocks 2 and 3 near commissioning: On track for completion by end of Q2 FY25. A CDMO contract with a reputed European originator is in the final stage of signing, expected by end of this quarter or early next quarter.
• Validation timeline: Validation batches are planned for next quarter (Q2 FY25), with gradual ramp-up through Q3 and Q4, targeting full ramp-up in FY26 across 84 country registrations.
• Fermion contract: Validation batches already sent; gradual increase from Q2 through Q4, with full peak utilization in FY26.
• Utilization philosophy: Management prioritizes high-value products over utilization-rate targets; continuous process improvement means utilization is a moving metric, and 85% within one year is not realistic.

Electrolytes & Battery Chemicals: Promise, Not Revenue

• Electrolyte additives CAPEX on track: Capacity expansion for VC and FEC up to 2,000 metric tonnes; completion targeted by end of FY25. Revenue expected to begin from H2 FY25 under a long-term contract already signed.
• Eight new additives in qualification: Additional molecules are at the qualification stage with various customers and with Enchem, broadening the pipeline beyond the initial two products.
• Enchem JV timeline undefined: The JV entity (Enchem AMI Organics Private Limited) is established as a wholly owned subsidiary, but finalization of JV terms is complicated by cross-border, cross-company, and regulatory requirements. Management declined to give any timeline.
• No material revenue yet: Electrolyte sales have not started; only small sampling invoices exist. The business remains in the working-out stage.

Competitive Positioning & Strategy

• Technology-driven niche insulates: Management argues that specialty players relying on technology-driven processes and niche products are less impacted by current market challenges, positioning AMI's CDMO and advanced pharma business defensively.
• Product mix shifting toward originator: Originator business will exceed 50% of the mix in future, though management declined to disclose exact numbers citing confidentiality. This shift supports the margin recovery narrative.
• Not peer-comparable: Management pushed back on margin comparisons with pure-play CDMO peers, noting AMI's basket spans originator, generic, and commodity specialty chemicals where margins are lower but volumes are high.
• Flow chemistry investment: New flow chemistry equipment at Sachin and Jhagadia is helping optimize capacity utilization, supporting the operational efficiency lever in the margin improvement plan.

Naresh Patel: "Specialty players, those relying on a technology-driven processes and niche products are less impacted by current market challenges."

Guidance & Commitments

Key Metrics